Day: March 10, 2022

One Liberty Properties Reports Fourth Quarter and Full Year 2021 Results

Written by Customer Service on March 10, 2022. Posted in Earnings Releases And Operating Results.

~ Occupancy at Quarter-End 99.2 % ~~ Strong Leasing in 2021 Positions Company for the Long-Term ~ GREAT NECK, N.Y., March 10, 2022 (GLOBE NEWSWIRE) — One Liberty Properties, Inc. (NYSE: OLP), a real estate investment trust focused on net leased properties, today announced operating results for the quarter and year ended December 31, 2021. Patrick J. Callan, Jr., President and Chief Executive Officer of One Liberty, “While successfully navigating the pandemic, we extended the term of significant leases and tenancies, and are pleased to end 2021 with occupancy at 99.2%. We also continue to successfully transform our portfolio to industrial focused properties as we believe that over the long-term this asset class will provide greater stability to our cashflow. We believe that over-time, the repositioning of the portfolio will support...

Net1 receives competition law approval in respect of the Connect Group transaction

Written by Customer Service on March 10, 2022. Posted in Mergers And Acquisitions.

JOHANNESBURG, South Africa, March 10, 2022 (GLOBE NEWSWIRE) — Net 1 UEPS Technologies, Inc. (NasdaqGS: UEPS; JSE: NT1) (“Net1,” or the “Company”) today announced that it has received approval from the South African, Botswanan and Namibian competition authorities in respect of its acquisition of 100% of the shares and claims in the Connect Group. The merger was approved unconditionally by the Botswana and Namibia competition authorities on January 12, 2022 and February 24, 2022 respectively, and by the South African competition authorities on March 9, 2022, subject to the merger conditions described below. The transaction completion is still subject to the finalization of certain outstanding conditions precedent, as described further below. Quote from Chris Meyer, Net1 Group CEO “We welcome the decision by the competition authorities...

Alto Ingredients, Inc. Reports Fourth Quarter and Full Year 2021 Results

Written by Customer Service on March 10, 2022. Posted in Earnings Releases And Operating Results.

Increased Net Sales 128% to $385 Million and Gross Profit 209% to $42 Million in Q4 2021 vs. Q4 2020 Improved Net Income Available to Common Stockholders to $35 Million from Net Loss of $21 Million and Adjusted EBITDA 168% to $43 Million in Q4 2021 vs. Q4 2020 Grew Net Sales 35% to $1.2 Billion and Gross Profit 28% to $68 Million in 2021 vs. 2020 Improved Net Income Available to Common Stockholders to $44 Million and Adjusted EBITDA 15% to $77 Million in 2021 vs. 2020 Acquired Specialty Alcohol Distributor, Eagle Alcohol, in January 2022SACRAMENTO, Calif., March 10, 2022 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols and essential ingredients, reported its fourth quarter and full year 2021 financial results for the year ended December 31, 2021. “In 2021, by...

Barfresh Provides Fourth Quarter and Full Year 2021 Results and Business Update

Written by Customer Service on March 10, 2022. Posted in Earnings Releases And Operating Results.

Company Achieves Highest Quarterly and Fiscal Year Revenue in Company History Fourth Quarter 2021 Revenue Increased 27% Sequentially and 296% Year-Over-Year to $2.5 Million; Full Year 2021 Revenue Increased 161% Year-Over-Year to $6.7 Million LOS ANGELES, March 10, 2022 (GLOBE NEWSWIRE) — Barfresh Food Group, Inc. (the “Company” or “Barfresh”) (Nasdaq: BRFH), a manufacturer of frozen, ready-to-blend and ready-to-drink beverages, is providing a business update in conjunction with the filing of its form 10-K for the full year ended December 31, 2021. Management Comments Riccardo Delle Coste, the Company’s Chief Executive Officer, stated, “We are pleased to have achieved our highest quarterly and fiscal year revenue and near-breakeven Adjusted EBITDA for the fourth quarter for the first time in our operating history. In addition,...

Neovasc Announces Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update

Written by Customer Service on March 10, 2022. Posted in Earnings Releases And Operating Results.

VANCOUVER and MINNEAPOLIS, March 10, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2021. HighlightsAchieved record revenue in Q4 of $759,000, an increase of 48% over the same period in 2020 Achieved record revenue in 2021 of $2.55 million, an increase of 30% over the prior year Commenced the COSIRA-II IDE clinical trial for Reducer in the United States Expanded reimbursement for the Reducer in the United States, UK, France and Germany Maintained strong financial footing and cash run rate into fiscal year 2024“The record fourth quarter and fiscal year 2021 were both pivotal for Neovasc,” said Fred Colen, President and Chief Executive Officer. “We began...

Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Written by Customer Service on March 10, 2022. Posted in Earnings Releases And Operating Results.

– XIPERE® -Related Milestones Generated $20 Million in Non-Dilutive Funding in Q4 2021 – – Continued Progress in CLS-AX OASIS Wet AMD Phase 1/2a Trial with Cohort 3 Results Expected Mid-2022 – – New Cohort 4 Planned in Q2 2022 to Expand CLS-AX Dose Escalation in OASIS Trial- – Management to Host Webcast and Conference Call Today at 4:30 P.M. ET – ALPHARETTA, Ga., March 10, 2022 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update. “Our suprachoroidal injection platform is a proven approach for ocular drug delivery that offers potential...

The Oncology Institute Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Strong Growth Outlook for 2022

Written by Customer Service on March 10, 2022. Posted in Earnings Releases And Operating Results.

CERRITOS, Calif., March 10, 2022 (GLOBE NEWSWIRE) — The Oncology Institute (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and full year ended December 31, 2021 and provided an update on its business including guidance for the year ending December 31, 2022. “We are very proud of the excellent care TOI delivered to our patients and communities in 2021, and we are excited to grow our business and help make a profound difference in the lives of our patients in 2022,” said Brad Hively, CEO of The Oncology Institute. “In 2021, we achieved record revenue of $203 million and we finished the year at approximately 1.6 million lives managed under value-based contracts. Notably, after the completion of our business combination transaction...

Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results

Written by Customer Service on March 10, 2022. Posted in Earnings Releases And Operating Results.

Strategic acquisition of SP-3164, a targeted protein degrader in development for hematologic and solid tumors, adds to pipeline of cancer therapies Clinical development of seclidemstat is continuing with updates from two Phase 1/2 clinical trials in sarcoma and hematologic cancer patients anticipated in 2022 Conference Call and Live Audio Webcast Scheduled for Today, March 10, 2022, 5:00 p.m. ET HOUSTON, March 10, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported important corporate events and its financial results for the full year and the fourth quarter ended December 31, 2021. “We believe the progress made by Salarius Pharmaceuticals during 2021 and the early weeks of 2022...

Histogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

Written by Customer Service on March 10, 2022. Posted in Earnings Releases And Operating Results.

Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023 SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided an update on its clinical pipeline and other corporate developments. “We have a diverse pipeline of biologics and small molecule product candidates that we believe address large unmet market needs,” said Steven J. Mento, Ph.D., Interim President and Chief Executive Officer. “Looking ahead, we will continue to focus on clinical...

Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates

Written by Customer Service on March 10, 2022. Posted in Earnings Releases And Operating Results.

— Ongoing Phase 1/2 clinical trial for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, is on track to report top line proof of concept data in the second quarter of 2022 — — VRDN-002, a distinct IGF-1R antibody incorporating validated half-life extension technology, expected to deliver top line Phase 1 clinical data in mid-2022 — — Strong cash and investment position of $197 million; current cash runway expected to fund operations into 2024 — — Conference call today at 4:30 p.m. ET — WALTHAM, Mass., March 10, 2022 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced financial results for the fourth quarter...

Day: March 10, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice